

THE USE OF AI FOR HIV, HEPATITIS AND STI PROGRAMMES

Purvi Shah


WHO, Global HIV, Hepatitis and STI programmes, Geneva UNAIDS, Regional Support team – Asia Pacific, Bangkok

PMAC 2025 1 February 2025





GAPS IN HIV, HEPATITIS AND STI PROGRAMMES







WHAT ARE VIRTUAL INTERVENTIONS



- Interventions that use any of the strategies or approaches virtually without coming face to face with the client is called virtual interventions.
- This can be internet or feature phone based awareness, social media posts, demand creation or mailing a HIV self test kit
- With the experience of COVID -19, globally HIV programs moved virtual
- Virtual interventions help programs to continue providing services to the populations without coming to the facility.











WHY SHOULD WE GO VIRTUAL?


- **5.45 billion internet users** (67% of total population)
- Avg 83% of youth rely on the internet for healthcare options
- 6.5 hours on internet
- Reach broader audience
- Targeted reach
- Offers choices
- Improves efficiency
- Saves cost
- Less time consuming






POLICY BRIEF - 2022


- Support programmes and governments to plan and implement virtual interventions to accelerate the progress towards meeting global goals
- Help programmes and governments to plan, adapt and implement safe and effective virtual service delivery during COVID-19 related restrictions and learn from these for future implementation.
- Provide guiding principles and an adaptable framework for virtual interventions to enable stakeholders to prioritize approaches and activities based on the country context and needs.
- Help programmes to identify technical assistance needs for approaches they would like to plan and implement.


















AI EXPERT CONSULTATION SUMMARY


Conducted by WHO in July 2024

OPPORTUNITIES FOR USING AI





Public Health Outcomes – Improved diagnosis, retention, self care and access



Festing

- Result interpretation/ linkage to prevention and care
- Self care option
- Access to information on testing
- Ease for HCW at POC
- Al for procurement processes
- Smart guidelines
- Regulating AI as a diagnostic tool
- Data sharing and privacy
- Multilingualism



Improved access to PrEP

- Al based risk assessment and analysis for offering PrEP
- Behaviour change communication through Chatbots and other Al channels
- Opportunity to address stigma
- Smart guidelines
- Shortage of domain experts
- Privacy
- Accountability and regulatory considerations



Retention in care & treatment adherence Preventing treatment interruption (prediction of risk)

- Treatment related information through telehealth (chatbots)
- Smart guidelines
- Quality of data collection
- Ability to scale
- Equity in implementing Al models in different health settings and geographies


World Health Organization

Strategic Information – 1. Improved data analysis and reporting 2. Improved routine data monitoring 3. Drug and Diagnostic stock gaps analysis 4. Patient monitoring and data collection for improving health services and outcomes 5. Access to WHO and other information.

JAMA Internal Medicine

Comparing Physician and Artificial Intelligence Chatbot Responses to Patient Questions Posted to a Public Social Media Forum

John W. Ayers, PhD, MA^{1,2}; Adam Poliak, PhD³; Mark Dredze, PhD⁴; et al





LOWER ACCESS BARRIERS VIA TELEHEALTH

Al model on Quality assured remote selftesting unlocks new channels for prevention, treatment, & retention

Self-testers



Buy self-test from online pharmacy



Guided self-test and Al-facilitated results capture



Al verified results



Clinician reviews Al decision support





Counselling, access to PrEP, PEP, or referral for follow-up care





AUTOMATED DATA CAPTURE AND ANALYTICS AVAILABLE AT ALL LEVELS







Write on paper



Take a picture



Get the data



Use the data







CHALLENGES AND CONSIDERATIONS



DATA PRIVACY AND SECURITY

Ensuring the privacy and security of user data is crucial for the widespread adoption of Alpowered tools in the healthcare domain.



LACK OF EVIDENCE DRIVEN DATA

The limited availability of high-quality, diverse datasets can hinder the development and validation of effective AI models for these infections.



EQUITY

Many nations face significant disparities in terms of technological infrastructure, digital literacy, and access to data.



COMPLACANCY AND RESISTANCE

Overcoming the reluctance of some service providers to adopt new technologies and ensuring their trust in Al-powered tools is a significant challenge.







SAFE AND ETHICAL USE OF ALIS CRITICAL


ŢŢ	ETHICS	Ensuring respect for patient autonomy, consent, and privacy.
	SAFETY AND PRIVACY	Protecting users from harm caused by AI errors or unintended consequences
	ACCURACY	Guaranteeing that AI predictions and recommendations are reliable and evidence-based.
	SECURITY	Safeguarding sensitive health data from breaches and unauthorized access or use.
Q	LOCAL CONTEXT	Adapting AI solutions to fit cultural, social, and healthcare realities on the ground.
	BIAS	Preventing algorithmic discrimination based on gender, race, socioeconomic status or any other factors.
٠١١٠	INFRASTRUCTURE	Addressing the lack of technological resources and connectivity needed for AI implementation.
	GOVERNANCE	Establishing clear policies and regulations to manage AI systems in healthcare.






WHAT'S NEXT WITH AI?

- Technical Brief on the use of Al for Testing and Prevention in HIV, Hepatitis and STI Programmes
- Support countries to understand and use Al ethically
- Work with Al experts and partners to chart possible solutions to current challenges





Key takeaway

WITH GREAT POWER COMES GREAT RESPONSIBILITY

THANK YOU



Connect: Purvi Shah, shahp@unaids.org



